Sodium fusidate in Gillain-Barré syndrome: a case report.
A patient with Guillain-Barré syndrome is reported on who responded favourably to a short course treatment with the novel immunosuppressant sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week. Along with prompt and clear cut clinical improvement, treatment with Fucidin was associated with a rapid decline in the blood concentrations of inflammatory cytokines presumably implicated in the pathogenesis of Guillain-Barré syndrome such as interleukin-2, interferon-gamma, and tumor necrosis factor-alpha. The ex vivo production of these cytokines was also markedly diminished compared with pretreatment values. Fucidin was well tolerated and no clinical or biochemical side effects were seen.
Institute of Microbiology, University of Milan, Italy. fnicol@herganet.it
F
F
Nicoletti
A
A
Nicoletti
S
S
Giuffrida
R
R
Di Marco
P
P
Meroni
K
K
Bendtzen
M
M
Lunetta
D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005672:Fusidic Acid / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000097:blood; D007376:Interleukin-2 / Q000097:blood; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D011129:Polyradiculoneuropathy / Q000188:drug therapy* / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D007166:Immunosuppressive Agents; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D005672:Fusidic Acid; D007371:Interferon-gamma